ArticleDiscover nano2025
Activity of silver-zinc nanozeolite-based antibiofilm wound dressings in an in vitro biofilm model and comparison with commercial dressings.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research on Silver-Based Wound Dressing: An Ontological Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Ag- and Zn-clinoptilolite: a comparison of their in-vitro antibacterial activity against Helicobacter pylori.Environmental geochemistry and health · 2025Article
- Antibiofilm activity of ZnO-Ag nanoparticles against Pseudomonas aeruginosa.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInfected wounds are a major health problem as infection can delay wound healing. Wound dressings play an important part in wound care by maintaining a suitable environment that promotes healing. Silver sulfadiazine dressings have been used to prevent infection in burn wounds. Presently, many commercial silver dressings have obtained FDA clearance.
resultsIn this study, we report on a novel silver dressing using microporous aluminosilicate zeolites, termed ABF-XenoMEM. Silver and zinc ions are encapsulated in the zeolite supercages. We show that the silver-zinc zeolite (AM30) alone is effective at inhibiting biofilm formation. The encapsulation protects the silver from rapidly precipitating in biological fluids. We exploit the negatively charged zeolite surface to associate positively charged quaternary ammonium ions (quat) with the zeolite. The combination of the AM30 with the quat enhances the antimicrobial activity. The colloidal nature of the zeolite materials makes it possible to make uniform deposits on a commercial extracellular matrix membrane to develop the final dressing (ABF-XenoMEM). The optimum loading of silver, zinc, and quat on the dressing was found to be 30, 3.7, and 221 µg/cm
conclusionThis study shows that the ABF-XenoMEM is competitive with extensively used commercial wound dressings in a colony biofilm model. Nanozeolite-entrapped silver/zinc antimicrobials in association with quat have the potential for application in biofilm-infected wounds and require animal and clinical studies for definitive proof.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.